304 related articles for article (PubMed ID: 32384177)
1. Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol; 2020 Aug; 95(8):978-989. PubMed ID: 32384177
[TBL] [Abstract][Full Text] [Related]
2. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol; 2018 May; 93(5):704-715. PubMed ID: 29634090
[TBL] [Abstract][Full Text] [Related]
3. Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol; 2022 Nov; 97(11):1478-1488. PubMed ID: 36215668
[TBL] [Abstract][Full Text] [Related]
4. Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol; 2016 Jun; 91(4):434-42. PubMed ID: 27001163
[TBL] [Abstract][Full Text] [Related]
5. Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol; 2014 Jul; 89(7):771-9. PubMed ID: 24953862
[TBL] [Abstract][Full Text] [Related]
6. Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol; 2012 Dec; 87(12):1096-103. PubMed ID: 23151980
[TBL] [Abstract][Full Text] [Related]
7. Annual clinical updates in hematological malignancies: a continuing medical education series. Hodgkin lymphoma: 2011 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol; 2011 Oct; 86(10):851-8. PubMed ID: 21922525
[TBL] [Abstract][Full Text] [Related]
8. SEOM clinical guidelines for the treatment of Hodgkin's lymphoma.
Rueda Domínguez A; Alfaro Lizaso J; de la Cruz Merino L; Gumá I Padró J; Quero Blanco C; Gómez Codina J; Llanos Muñoz M; Martinez Banaclocha N; Rodriguez Abreu D; Provencio Pulla M
Clin Transl Oncol; 2015 Dec; 17(12):1005-13. PubMed ID: 26497354
[TBL] [Abstract][Full Text] [Related]
9. Hodgkin Lymphoma: Diagnosis and Treatment.
Ansell SM
Mayo Clin Proc; 2015 Nov; 90(11):1574-83. PubMed ID: 26541251
[TBL] [Abstract][Full Text] [Related]
10. Progress in the initial management of Hodgkin's Lymphoma.
Marri PR; Ansell SM
Transfus Apher Sci; 2013 Aug; 49(1):12-8. PubMed ID: 23769695
[TBL] [Abstract][Full Text] [Related]
11. Management of Hodgkin lymphoma.
Ansell SM; Armitage JO
Mayo Clin Proc; 2006 Mar; 81(3):419-26. PubMed ID: 16529147
[TBL] [Abstract][Full Text] [Related]
12. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
[TBL] [Abstract][Full Text] [Related]
13. Hodgkin lymphoma.
Gobbi PG; Ferreri AJ; Ponzoni M; Levis A
Crit Rev Oncol Hematol; 2013 Feb; 85(2):216-37. PubMed ID: 22867814
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.
Zinzani PL; Pellegrini C; Cantonetti M; Re A; Pinto A; Pavone V; Rigacci L; Celli M; Broccoli A; Argnani L; Pulsoni A
Oncologist; 2015 Dec; 20(12):1413-6. PubMed ID: 26500229
[TBL] [Abstract][Full Text] [Related]
15. Treatment of relapsed and refractory Hodgkin Lymphoma.
von Tresckow B; Moskowitz CH
Semin Hematol; 2016 Jul; 53(3):180-5. PubMed ID: 27496309
[TBL] [Abstract][Full Text] [Related]
16. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.
Rancea M; Monsef I; von Tresckow B; Engert A; Skoetz N
Cochrane Database Syst Rev; 2013 Jun; (6):CD009411. PubMed ID: 23784872
[TBL] [Abstract][Full Text] [Related]
17. Hodgkin lymphoma, version 2.2015.
Hoppe RT; Advani RH; Ai WZ; Ambinder RF; Aoun P; Bello CM; Benitez CM; Bierman PJ; Blum KA; Chen R; Dabaja B; Forero A; Gordon LI; Hernandez-Ilizaliturri FJ; Hochberg EP; Huang J; Johnston PB; Khan N; Maloney DG; Mauch PM; Metzger M; Moore JO; Morgan D; Moskowitz CH; Mulroney C; Poppe M; Rabinovitch R; Seropian S; Tsien C; Winter JN; Yahalom J; Burns JL; Sundar H;
J Natl Compr Canc Netw; 2015 May; 13(5):554-86. PubMed ID: 25964641
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for the treatment of Hodgkin lymphoma.
Donato EM; Fernández-Zarzoso M; De La Rubia J
Expert Rev Hematol; 2017 May; 10(5):417-423. PubMed ID: 28359170
[TBL] [Abstract][Full Text] [Related]
19. Advanced and relapsed/refractory Hodgkin lymphoma: what has been achieved during the last 50 years.
Vassilakopoulos TP; Angelopoulou MK
Semin Hematol; 2013 Jan; 50(1):4-14. PubMed ID: 23507479
[TBL] [Abstract][Full Text] [Related]
20. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
